Staff Contact: Kara Amann-Kale or Keri Barclay
Pfizer and BioNTech submitted an application for EUA of a second booster dose of its COVID-19 vaccine for adults ages 65 years and older who have received an initial booster of any authorized COVID-19 vaccine. Real-world data indicate infection rates were two times lower and severe illness rates were four times lower for individuals who received a second booster compared to those who only received one booster dose.
The FDA and CDC must authorize use of boosters for this population before administration can begin. Separately, the FDA Vaccines and Related Biological Products Advisory Committee is convening in April to discuss considerations for 2022 booster shots; however, a date for that meeting has yet to be set.